Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. by Kruit, W. H. et al.
BriUs Jou d Caof e (195 71,1319-1321
© 1995 Stockton Press AJI rihts reserved 0007-0920/95 $12.00 %
Final report of a phase H study of interleukin 2 and interferon a in
patients with metastatic melanoma
WHJ Kruit', SH Goey', F Calabresi2, A Lindemann3, RA Stahel4, H Poliwoda5, B Osterwalder6
and G Stoter'
'Department ofMedical Oncologv, Rotterdam Cancer Institute, PO Box 5201, 3008 AE Rotterdamn, The Netherlands;
2Department ofMedical Oncology, National Cancer Institute Regina Elena, Viale Regina Elena 291, 00161 Rome, Italy;
3Department ofHematology and Oncology, University Hospital, Hugstetter Str 55, D-79106 Freiburg, Germany; 4Division of
Oncology, Department ofMedicine, University Hospital, CH-8091 Zurich, Switzerland; 5Department ofHematology and
Oncology, University Medical Center, D-3000 Hannover 61, Germany; 6International Clinical Research Oncology, F Hoffmann-La
Roche Ltd, Gren-acherstrasse 124, 4002 Basle, Switzerland.
Summary Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU
m- day as a continuous infusion for 4 days combined with interferon a (IFN-a) 6 MIU m day-'
subcutaneously on days I and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles.
Of the 51 evaluable patients, one (2%) achieved a complete and seven (14%) a partial response (total response
rate 16%: C1 7-29%). Median time to progression and median survival were 2.5 and 11.3 months respectively.
This regimen of IL-2 and IFN-a appeared to be only moderately active.
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Immunotherapy with recombinant interleukin 2 (IL-2) has
been reported to yield a 5-27% response rate in metastatic
melanoma (Rosenberg et al., 1989a, 1993; Parkinson et al.,
1990; Whitehead et al., 1991; Sparano et al., 1993). Inter-
feron x (IFN-() alone in this group of patients has shown
response rates of 12-22% (Robinson et al., 1986; Kirkwood,
1991).
Based on the synergistic activity of IL-2 and IFN-a in
preclinical experiments (Brunda et al., 1987; Cameron et al.,
1988; ligo et al., 1988) and on the encouraging results of
early clinical trials with this combination (Budd et al., 1989;
Lee et al., 1989; Rosenberg et al., 1989b), we decided to
perform a phase II study. Here, we report the final analysis
after a median follow-up period of 10.5 months (range
1.1 -47+ months).
and toxicity. The patient characteristics are shown in Table I.
The median time from initial diagnosis to immunotherapy
was 24 months (range 1-142 months).
Treatment
Patients were treated with IL-2 at a dose of 7.8 MIU m-2
day-' by continuous infusion on days 1-4 and with IFN-(-
2a 6MIUm2 day-' by subcutaneous injection on days 1
and 4 of each treatment cycle. IL-2 (Teceleukin) and IFN-a
(Roferon-A) were supplied by Hoffmann-LaRoche, Basle,
Switzerland. Cycles were repeated every 2 weeks.
Evaluation of response was performed after 4 cycles and
every 2 months thereafter. Patients who responded or
experienced no change received nine additional treatment
cycles. Further continuation of treatment beyond 6 months
was allowed.
Materials and methods
Patients
Fifty-seven patients with metastatic melanoma were entered
in the study. Eligibility criteria included: age 18-70 years,
Karnofsky performance status 60-100, no metastases in the
central nervous system, no significant cardiovascular history,
normal pulmonary function, serum bilirubin and creatinine
within normal range, normal bone marrow function (haema-
tocrit>30%, white blood count>4000ml-1, platelets>
100 000 ml'), normal coagulation parameters, normal serum
calcium and negative tests for HIV antibody and hepatitis B
antigen.
Previous treatment with IL-2 or IFN-a was not allowed.
Prior radiotherapy or chemotherapy had to be completed at
least 4 weeks before entry into the study. Corticosteroids
were prohibited.
The protocol was reviewed and approved by the institu-
tional review board and the ethical committee of each par-
ticipating centre.
Six patients were ineligible; three had non-measurable
disease, two had brain metastases, one was pretreated with
interferon 2p. Fifty-one patients were evaluable for response
Table I Patient characteristics
Number of patients
Age (years)
Median
Range
Sex
Male
Female
Performance status (Kamofsky)
Median
Range
Prior therapy
None
Chemotherapy
Radiotherapy
Hormone therapy
Distribution of metastatic sites
Lung
Lymph nodes
Skin
Liver
Bone
Number of metastatic sites
2
3
4
5
6
51
49
21 -72
29 (57%)
22 (43%)
90
70- 100
25 (49%)
19 (37%)
5 (10%)
2 (4%)
20 (39%)
29 (57%)
16 (31%)
17 (33%)
10 (20%)
15 (29%)
14 (27%)
10 (20%)
9 (18%)
2 (4%)
1 (2%)
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Monitoring
Toxicity was recorded and analysed using the WHO grading
system (WHO, 1979). Side-effects not described in the WHO
guidelines were graded from mild (grade 1) to life-threatening
(grade 4).
Response was evaluated according to the WHO guidelines
(WHO, 1979). A complete response (CR) was defined as the
disappearance of all known disease for at kast 4 weeks. A
partial response (PR) was defined as a reduction in the sum
of the products of the largest perpendicular diameters of the
tumour lesions by at least 50% for more than 4 weeks. Stable
disease (SD) denoted less than 50% tumour reduction and
less than 25% tumour progression. Progressive disease (PD)
was defined as the appearance of a new lesion or an increase
in size of more than 25% in any lesion.
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Response
Of the 51 eligible patients, 24 (47%) received 2-4 treatment
cycles, 12 (24%) 5-8 cycles, 13 (26%) 9-13 cycles, one
patient 15 and one patient 16 cycles. Four patients were
taken off study early, one because of intercurrent illness and
three because of grade 4 toxicity.
The overall response rate was 16% (95% confidence inter-
val 7-29%), including one CR (2%) and seven PRs (14%).
Twenty patients (39%) had stable disease. In 23 (45%)
patients progresive disease was documented. Three of the
responders were male and five were female. Responses were
seen in skin ksions (36%), lymph nodes (27%), lung (18%)
and liver (18%). Of note, bone metastases did not respond.
All responses occurred in the first 3 months of treatment.
The median duration of response was 8.2 months (range
4.5-39+ months). For all 51 patients the median time to
progression was 2.5 months (range 0.5-39+ months). Time
to progression for responding patients was 8.2 months (range
4.5-39+ months), for patients with stable disease 3.6
months (range 1.7-9.4 months) and for progressive disease
patients 1.2 months (range 0.5-2.0 months). The median
survival of all patients was 11.3 months (Figure 1), and of
the responding patients 20.2 months.
Toxicity
An overview of the observed toxicity is presented in Table H.
Frequently occurring side-effects were fever, skin rash,
nausea, vomiting, diarrhoea and malaise. Two-thirds of
patients had tachycardia and hypotension, mostly of mild to
moderate grade. Life-threatening hypotension requiring vaso-
pressors occurred in three patients, who were taken off study
(see above). One patient developed ventricular extrasystoles
and another patient atrial fibrillation. In a minority of
patients neurological abnormalities and mental disturbances
were seen, Neurotoxicity included aphsia, peripheral neuro-
pathy, somnolence, confusion and agitation.
Two patients required dose reductions because of adverse
events, and in eight patients short interruption of treatment
was needed. Not toxic death occurred and all toxicties
resolved after cessation of immunotherapy. Chronic cumula-
tive fatigue occurred after about 3 months of treatment.
Consequently, only two patients received more than 13
cycles.
The most frequent manifestation ofhaematological toxicity
was anaemia (71%). Thrombocytopenia was seen in 18% of
the patients. Moderate and reversible increases in serum
creatinine and bilirubin occurred in a minority of patients.
In this study the combined use of IL-2 and IFN-z in the
treatment of metastatic melanoma resulted in a 16% res-
Table n Adverse events
Nwnber of
Adverse events patients (%) 1 2 3 4
Fever 51 (100) 0 21 30 0
Skin rash/erythema 36 (71) 13 19 4 0
Nausea/vomiting 48 (94) 7 28 13 0
Diarrhoea 38 (75) 10 20 8 0
Malaise 29 (57) 4 15 10 0
Weight gain 15 (30) 13 2 0 0
Hypotenson 39 (76) 7 18 11 3
Tachycardia 36 (71) 13 20 3 0
Dyspnoea 10 (20) 4 4 2 0
Mental disturbances 8 (16) 5 3 0 0
Creatinine 19 (37) 16 3 0 0
Alkaline phosphatase 30 (59) 12 15 3 0
Bilirubin 9 (18) 7 2 0 0
Anacmia 36 (71) 17 14 5 0
Thrombocytopenia 9 (18) 7 2 0 0
ponse rate, including 2% complete responses. These results
are disappointing and not better than can be expected of
conventional chemotherapy or immunotherapy with IL-2
alone.
Response rates of 21-44% have been reported in some
studies using the combination of both cytokines (Lee et al.,
1989; Rosenberg et al., 1989b; Budd et al., 1992). However,
low response rates of 10% or less were observed by others
(Olham et al., 1992; Dillman et al., 1993; Sparano et al.,
1993). The median response duration in these trials varied
between 2 and 11 months, and the median survival was
approximately 10 months (Lee et al., 1989; Rosenberg et al.,
1989b; Oldham et al., 1992; Dillman et al., 1993; Sparano et
al., 1993). We achieved similar results.
We failed to confirm the ability of IFN-a to augment the
effect of IL-2. This may have been due to suboptimal dose
and schedule. Our patients received moderate doses of IL-2.
In animal studies the efficacy of IL-2 is dose dependent
without reaching a plateau below the maximum tolerated
dose (Mule et al., 1984). However, in trials using high-dose
IL-2 (18 MIU m2 day-') given by continuous infusion in
patients with metastatic melanoma inferior response rates
were reported (Oldham et al., 1992; DilIman et al., 1993). An
NCI Surgery Branch Study, administering high-dose bolus
IL-2 (>30 MIU m-2day-') and IFN-a found the highest
response rates (Rosenberg et al., 1989b). On the other hand,
the Extramural IL-2 Working Group, using identical dose,
schedule and patient selection criteria, did not observe any
evidence of enhanced response with the IL-2/IFN-a combina-
tion (Sparano et al., 1993). In summary, a dose-response
effect for IL-2 in the treatment ofmetastatic melanoma is not
clear.
The side-effects we observed were of similar incidence and
severity as reported previously (Lee et al., 1989; Rosenberg et
al., 1989b; Budd et al., 1992; Oldham et al., 1992; Sparano etIntkrkdin 2 and inkrferon : in meastic meanoma
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al., 1993). Toxicity was manageable and patients tolerated
the therapeutic regimen relatively well. However, cumulative
fatigue made it impossible to give patients more than 13
cycles of therapy.
In conclusion, combined therapy with IL-2 and IFN-a in
the described regimen has only moderate activity in the
treatment of patients with metastatic melanoma. Further
clinical trials have to be designed to improve therapeutic
results.
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